April 5th 2024
Three distinct congresses known as RAVE (Revolutionizing Atopic Dermatitis, Alopecia Areata, and Vitiligo) will be held June 8-10, in Chicago, Illinois.
March 22nd 2024
Explore recent research that shed light on potential associations and manifestations post-COVID-19 infection or vaccination.
March 18th 2024
The data suggests that the medication, which targets specific cellular pathways, promotes hair regrowth in AA with minimal adverse effects.
March 12th 2024
Ronda Farah, MD, FAAD, reviews top hair loss pearls from her 5 sessions at AAD 2024.
March 6th 2024
In this week’s Pointers With Portela, the 208SkinDoc answers common hair loss questions.
Nektar Announces Initiation of Phase 2b Study for Rezpegaldesleukin in Severe, Very Severe Alopecia
The study will evaluate rezpegaldesleukin and its effect on Severity of Alopecia Tool scoring by the conclusion of a 36-week period.
Experts Review Key Factors in Alopecia Areata Severity and Morbidity Index, Treatment Decisions
Factors including disease duration, treatment response, and mental health were listed as crucial factors in severity and treatment.